OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Interpreting Randomized Controlled Trials
Pavlos Msaouel, Juhee Lee, Peter F. Thall
Cancers (2023) Vol. 15, Iss. 19, pp. 4674-4674
Open Access | Times Cited: 15
Pavlos Msaouel, Juhee Lee, Peter F. Thall
Cancers (2023) Vol. 15, Iss. 19, pp. 4674-4674
Open Access | Times Cited: 15
Showing 15 citing articles:
Postprogression therapy and confounding for the estimated treatment effect on overall survival in phase III oncology trials
Alexander D. Sherry, Pavlos Msaouel, Timothy A. Lin, et al.
BMJ Oncology (2024) Vol. 3, Iss. 1, pp. e000322-e000322
Open Access | Times Cited: 5
Alexander D. Sherry, Pavlos Msaouel, Timothy A. Lin, et al.
BMJ Oncology (2024) Vol. 3, Iss. 1, pp. e000322-e000322
Open Access | Times Cited: 5
Increasing Power in Phase III Oncology Trials With Multivariable Regression: An Empirical Assessment of 535 Primary End Point Analyses
Alexander D. Sherry, Adina H. Passy, Zachary R. McCaw, et al.
JCO Clinical Cancer Informatics (2024), Iss. 8
Closed Access | Times Cited: 4
Alexander D. Sherry, Adina H. Passy, Zachary R. McCaw, et al.
JCO Clinical Cancer Informatics (2024), Iss. 8
Closed Access | Times Cited: 4
Survival-Inferred Fragility of Statistical Significance in Phase III Oncology Trials
Alexander D. Sherry, Yufei Liu, Pavlos Msaouel, et al.
medRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
Alexander D. Sherry, Yufei Liu, Pavlos Msaouel, et al.
medRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
Sunitinib for the treatment of phaeochromocytomas and paragangliomas
Alexander D. Sherry, Ethan B. Ludmir, Pavlos Msaouel
The Lancet (2025) Vol. 405, Iss. 10476, pp. 380-381
Closed Access
Alexander D. Sherry, Ethan B. Ludmir, Pavlos Msaouel
The Lancet (2025) Vol. 405, Iss. 10476, pp. 380-381
Closed Access
Treatment group-specific inferences in Phase III Randomized Oncology Trials
Alexander D. Sherry, Adina H. Passy, Joseph Abi Jaoude, et al.
Acta Oncologica (2025) Vol. 64, pp. 470-474
Open Access
Alexander D. Sherry, Adina H. Passy, Joseph Abi Jaoude, et al.
Acta Oncologica (2025) Vol. 64, pp. 470-474
Open Access
Realizing self-determination theory in virtual healthcare training: evidence from cancer patients’ and family members’ learning achievement and decisional conflict
Gwo‐Jen Hwang, C.-C. Chou, Chun‐Chun Chang
Interactive Learning Environments (2025), pp. 1-21
Closed Access
Gwo‐Jen Hwang, C.-C. Chou, Chun‐Chun Chang
Interactive Learning Environments (2025), pp. 1-21
Closed Access
Differential Treatment Effects of Subgroup Analyses in Phase 3 Oncology Trials From 2004 to 2020
Alexander D. Sherry, Andrew W. Hahn, Zachary R. McCaw, et al.
JAMA Network Open (2024) Vol. 7, Iss. 3, pp. e243379-e243379
Open Access | Times Cited: 3
Alexander D. Sherry, Andrew W. Hahn, Zachary R. McCaw, et al.
JAMA Network Open (2024) Vol. 7, Iss. 3, pp. e243379-e243379
Open Access | Times Cited: 3
Evidenced-Based Prior for Estimating the Treatment Effect of Phase III Randomized Trials in Oncology
Alexander D. Sherry, Pavlos Msaouel, Gabrielle S. Kupferman, et al.
JCO Precision Oncology (2024), Iss. 8
Closed Access | Times Cited: 3
Alexander D. Sherry, Pavlos Msaouel, Gabrielle S. Kupferman, et al.
JCO Precision Oncology (2024), Iss. 8
Closed Access | Times Cited: 3
Decoding Randomized Controlled Trials: An Information Science Perspective
Pavlos Msaouel
Harvard data science review (2024) Vol. 6, Iss. 2
Open Access | Times Cited: 2
Pavlos Msaouel
Harvard data science review (2024) Vol. 6, Iss. 2
Open Access | Times Cited: 2
Towards Treatment Effect Interpretability: A Bayesian Re-analysis of 194,129 Patient Outcomes Across 230 Oncology Trials
Alexander D. Sherry, Pavlos Msaouel, Gabrielle S. Kupferman, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 2
Alexander D. Sherry, Pavlos Msaouel, Gabrielle S. Kupferman, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 2
Association of Tumor Mutational Burden and Microsatellite Instability With Response and Outcomes in Patients With Urothelial Carcinoma Treated With Immune Checkpoint Inhibitor
Dimitra Rafailia Bakaloudi, Rafee Talukder, Dimitrios Makrakis, et al.
Clinical Genitourinary Cancer (2024) Vol. 22, Iss. 6, pp. 102198-102198
Closed Access | Times Cited: 2
Dimitra Rafailia Bakaloudi, Rafee Talukder, Dimitrios Makrakis, et al.
Clinical Genitourinary Cancer (2024) Vol. 22, Iss. 6, pp. 102198-102198
Closed Access | Times Cited: 2
An Evidenced-Based Prior for Estimating the Treatment Effect of Phase III Randomized Trials in Oncology
Alexander D. Sherry, Pavlos Msaouel, Gabrielle S. Kupferman, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Alexander D. Sherry, Pavlos Msaouel, Gabrielle S. Kupferman, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Lost in the plot: missing visual elements in Kaplan-Meier plots of phase III oncology trials
Alexander D. Sherry, Pavlos Msaouel, Ramez Kouzy, et al.
The Oncologist (2024) Vol. 29, Iss. 7, pp. 547-550
Open Access | Times Cited: 1
Alexander D. Sherry, Pavlos Msaouel, Ramez Kouzy, et al.
The Oncologist (2024) Vol. 29, Iss. 7, pp. 547-550
Open Access | Times Cited: 1
Impact of postprogression therapies on overall survival: Recommendations from the 2023 kidney cancer association think tank meeting
Stephanie Berg, Salvatore La Rosa, Tian Zhang, et al.
Urologic Oncology Seminars and Original Investigations (2024)
Open Access | Times Cited: 1
Stephanie Berg, Salvatore La Rosa, Tian Zhang, et al.
Urologic Oncology Seminars and Original Investigations (2024)
Open Access | Times Cited: 1
Improving the clinical meaning of surrogate endpoints: An empirical assessment of clinical progression in phase III oncology trials
Alexander D. Sherry, Timothy A. Lin, Zachary R. McCaw, et al.
International Journal of Cancer (2024) Vol. 155, Iss. 11, pp. 1939-1943
Closed Access
Alexander D. Sherry, Timothy A. Lin, Zachary R. McCaw, et al.
International Journal of Cancer (2024) Vol. 155, Iss. 11, pp. 1939-1943
Closed Access
